Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Acasunlimab (GEN1046) in Japanese patients with advanced solid tumors
NCT04937153Phase 1Completed
- Sponsor
- Genmab
- Start
- Jun 2021
- Primary completion
- Oct 2024
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of acasunlimab in solid tumor (2 arms), sponsored by Genmab. Primary endpoints: Number of Participants with Dose limiting Toxicities at 21 days, Number of Participants with Adverse Events and 5 more. Started Jun 2021; status: completed.
02
Drugs
acasunlimab
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT04937153.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04937153.